Alimera Sciences, Inc.(NASDAQ : ALIM)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading ALIM News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.04%||68.55||0.9%||$505.54m|
|REGN||Regeneron Pharmaceuticals, Inc.||5.97%||388.49||2.7%||$332.95m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.69%||127.78||1.9%||$250.96m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.75%||118.30||1.9%||$235.75m|
|NBIX||Neurocrine Biosciences, Inc.||-0.36%||53.40||5.3%||$114.24m|
|BMRN||BioMarin Pharmaceutical Inc.||-0.40%||95.88||4.5%||$113.09m|
|KITE||Kite Pharma, Inc.||-0.68%||82.08||16.6%||$94.29m|
|A||Agilent Technologies, Inc.||-0.70%||55.04||1.5%||$93.33m|
|SRPT||Sarepta Therapeutics, Inc.||4.44%||36.26||19.8%||$82.73m|
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.